| Title: | Characteristics and Lenvatinib Treatment Response of Unresectable Hepatocellular Carcinoma with Iso-High Intensity in the Hepatobiliary Phase of EOB-MRI |
| Authors: | Kubo, Akinori Browse this author |
| Suda, Goki Browse this author →KAKEN DB |
| Kimura, Megumi Browse this author |
| Maehara, Osamu Browse this author |
| Tokuchi, Yoshimasa Browse this author |
| Kitagataya, Takashi Browse this author |
| Ohara, Masatsugu Browse this author |
| Yamada, Ren Browse this author |
| Shigesawa, Taku Browse this author |
| Suzuki, Kazuharu Browse this author |
| Kawagishi, Naoki Browse this author |
| Nakai, Masato Browse this author |
| Sho, Takuya Browse this author |
| Natsuizaka, Mitsuteru Browse this author |
| Morikawa, Kenichi Browse this author |
| Ogawa, Koji Browse this author |
| Ohnishi, Shunsuke Browse this author |
| Sakamoto, Naoya Browse this author →KAKEN DB |
| Keywords: | CTNNB-1 |
| HCC with iso-high intensity in the hepatobiliary phase of EOB-MRI |
| Lenvatinib |
| Issue Date: | Jul-2021 |
| Publisher: | MDPI |
| Journal Title: | Cancers |
| Volume: | 13 |
| Issue: | 14 |
| Start Page: | 3633 |
| Publisher DOI: | 10.3390/cancers13143633 |
| Abstract: | In hepatocellular carcinoma (HCC), CTNNB-1 mutations, which cause resistance to immune checkpoint inhibitors, are associated with HCC with iso-high intensity in the hepatobiliary phase of gadoxetic acid-enhanced magnetic resonance imaging (EOB-MRI) in resectable HCC; however, analyses on unresectable HCC are lacking. This study analyzed the prevalence, characteristics, response to lenvatinib, and CTNNB-1 mutation frequency in unresectable HCC with iso-high intensity in the hepatobiliary phase of EOB-MRI. In 52 patients with unresectable HCC treated with lenvatinib, the prevalence of iso-high intensity in the hepatobiliary phase of EOB-MRI was 13%. All patients had multiple HCCs, and 3 patients had multiple HCCs with iso-high intensity in the hepatobiliary phase of EOB-MRI. Lenvatinib response to progression-free survival and overall survival were similar between patients with or without iso-high intensity in the hepatobiliary phase of EOBMRI. Seven patients (three and four patients who had unresectable HCC with or without iso-high intensity in the hepatobiliary phase of EOB-MRI, respectively) underwent genetic analyses. Among these, two (67%, 2/3) who had HCC with iso-high intensity in the hepatobiliary phase of EOB-MRI carried a CTNNB-1 mutation, while all four patients who had HCC without iso-high intensity in the hepatobiliary phase of EOB-MRI did not carry the CTNNB-1 mutation. This study's findings have clinical implications for the detection and treatment of HCC with iso-high intensity in the hepatobiliary phase of EOB-MRI. |
| Type: | article |
| URI: | http://hdl.handle.net/2115/82549 |
| Appears in Collections: | 北海道大学病院 (Hokkaido University Hospital) > 雑誌発表論文等 (Peer-reviewed Journal Articles, etc)
|
